$25,000 Match
Home | News | Events | Press | Contact  

About UseNewsletterMessage BoardsAction CenterAdvocateWalk to End Alzheimer’sShopDonate

Find your chapter:

search by state

Alzheimer News 7/01/2005
Text Size controlsNormal font sizeMedium font sizeLarge font size

Reminyl becomes Razadyne

Effective today, galantamine’s trade name changes from Reminyl to Razadyne. Manufacturer Ortho-McNeil Neurologics changed the name because doctors and pharmacists occasionally confused Reminyl with Amaryl (glimepiride), a diabetes drug prescribed to reduce blood sugar. Lowering blood sugar in individuals who do not have higher-than-normal levels is potentially harmful. Two individuals who mistakenly received Amaryl died.

In December 2004, the U.S. Food and Drug Administration (FDA) approved a new "extended release" form of galantamine designed to be taken once a day. That product became available in May 2005 as Razadyne ER.

For more information, please see:

  • An Alzheimer’s Association Oct. 27, 2004, research news story: "Consumer Alert: Check Your Alzheimer Medicine"

  • An Alzheimer’s Association fact sheet on cholinesterase inhibitors

  • Ortho-McNeil’s Razadyne Web site


Sign up for our e-newsletter

Stay up-to-date on the latest news and advances in Alzheimer's treatments, care and research. Get tips for living with Alzheimer's as well as simple ideas on how you can support the fight to end Alzheimer's.

First name: Last name:

*Email: *Zip:

The Alzheimer's Association does not share e-mail addresses with third parties. Please read our security and privacy policy.

Alzheimer's Association

Our vision is a world without Alzheimer's
Formed in 1980, the Alzheimer's Association is the world's leading voluntary health organization in Alzheimer's care, support and research.